CLAVACILLIN- amoxicillin anhydrous and clavulanate potassium tablet
Dechra Veterinary Products LLC
----------
Clavacillin™
(amoxicillin trihydrate/clavulanate potassium)
Veterinary Tablets
For use in dogs and cats
CAUTION:
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION:
Clavacillin (amoxicillin trihydrate/clavulanate potassium) is an orally administered formulation comprised of the broad-spectrum antibiotic amoxicillin trihydrate and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chemically, it is D(-)-α-amino-p-hydroxybenzyl penicillin trihydrate. Clavulanic acid, an inhibitor of β-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chemically, clavulanate potassium is potassium z-(3R,5R)-2-β-hydroxyethylidene clavam-3-carboxylate.

INDICATIONS:
Clavacillin Tablets are indicated in the treatment of: Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate/clavulanate potassium has been shown to be clinically effective for treating cases of canine periodontal disease.
Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to
susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-βlactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and
Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
Therapy may be initiated with Clavacillin prior to obtaining results from bacteriological and
susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the
organisms to Clavacillin. Following determination of susceptibility results and clinical response to
medication, therapy may be reevaluated.
CONTRAINDICATIONS:
The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.
WARNINGS:
Safety of use in pregnant or breeding animals has not been determined. Store at controlled room temperature, 68-77°F (20-25°C). Do not remove from foil strip until ready to use.
ADVERSE REACTIONS:
Clavacillin contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic
reactions. If an allergic reaction occurs, administer epinephrine and/or steroids. To report suspected adverse events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dechra at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or http://www.fda.gov/AnimalVeterinary/SafetyHealth.